Australia's Noxopharm rises on developing new mRNA 'vaccine enhancer' product

Noxopharm

28/03/2023 04:55

** Shares of Noxopharm Ltd  NOX.AX  climb as much as 3.2% to
A$0.098, post their biggest intraday pct gain since March 23 
    ** The drug developer says it has created an mRNA "vaccine
enhancer" to improve the effectiveness of vaccines and reduce
inflammation
    ** Says it has selected a lead candidate for further
development, and the product — called SOF-VAC — will be part of
co's Sofra preclinical platform
    ** Says SOF-VAC is the smallest known molecule of its type
to have demonstrated "strong activity" against inflammation
    ** NOX is developing the product in partnership with the
Hudson Institute of Medical Research
    ** Stock down 34.5% YTD, as of last close 
    


 (Reporting by Riya Sharma in Bengaluru)
 ((Riya.Sharma@thomsonreuters.com;))